StockData

Lyell Immunopharma vs NeOnc Technologies

LYEL and NTHI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LYEL and NTHI compare

Lyell Immunopharma is the larger company, worth 3.0 times as much as NeOnc Technologies ($359M against $118M).

Lyell Immunopharma scores higher on the StockData Score (6 against 0 for NeOnc Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLYELNTHI
Size and price
Market cap$359M$118M
Share price$14.65$4.54
Change, 1 year−15.9%−49.4%
Change, 5 years−92.1%–
Beta (5Y)1.272.75
Employees–5
StockData Score
Total score6 (better)0
Valuation score1 (better)0
Growth score00
Performance score00
Health score5 (better)0
Dividend score00
Valuation
P/S13296×–
P/B1.5×–
FCF yield−37.3%–
Growth
Revenue growth (TTM)−55.0%–
Revenue growth, 5Y average−65.9%–
Profitability
Operating margin−949981%–
Net margin−920285%–
FCF margin−496189%–
Return on equity−93.3%–
Return on invested capital−782%–
Financial health
Debt / equity0.00–
Interest coverage–−15.7×
Current ratio5.36 (better)0.38
Altman Z-score−6.86 (better)−34.16
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions48.9%12.2%
Held by insiders45.0%60.1%
Insider net buying, 12 months$74.4M (better)$2.0M
Short interest, % of float10.5%8.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.